Frost & Sullivan's analysts comment on India’s plan to invest in the Russian pharmaceutical industry

India is ready to invest in the Russian pharmaceutical industry, including India-Russia joint ventures, as India's Commerce and Industry Minister, Anand Sharma, said during his visit to Russia last week. Among other resources and technologies, India is very keen in developing biotechnologies, nanotechnologies and other sciences such as genomics and bioinformatics, thereby entering the Russian healthcare industry.

"India is one of the largest manufacturers of generics in the market. At present, Russia is making a list of all the prescribed medicines it needs and Indian and Russian governments are working on a protocol which will stipulate production, manufacturing capabilities and safety standards. Top drug therapeutic areas in Russia include CNS, anti-diabetics, cold and cough medications," says Frost & Sullivan Research Analyst, Ms. Swetha Shantikumar.

"In the late 90s and early 2000s, there was a very strong pharma import activity from India to Russia. At that time, Russia's main objective was to clear its debt through the Centralized Purchase System (CPS) by buying out useful commodities from India, in which pharmaceuticals also formed a major bulk," she continuous.

"A potential cooperation between Russia and India seems very beneficial for both parties. Indian manufacturers can benefit from the fact that Russia is in the midst of pharmaceutical sector reform, known as Pharma 2020, which aims at strengthening the domestic production capacities," adds Frost & Sullivan Consulting Analyst, Miss Dominika Grzywinska. "Therefore, those pharmaceutical companies which decide to open their production facilities in the country can count on certain sets of privileges, such as lower taxes or easier access to reimbursement lists. The entry of Indian pharmaceutical companies will help Russia fulfill the assumptions of the Pharma 2020 reform, i.e. making pharmaceuticals more accessible to citizens, strengthening domestic production and containing the ever-growing expenditure on drugs."

If you are interested in more information on this topic or would like to speak to Frost & Sullivan's analysts, please e-mail Katja Feick, Corporate Communications, at This email address is being protected from spambots. You need JavaScript enabled to view it., with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit